Hans de Haard

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

Peter Ulrichts, Antonio Guglietta, Torsten Dreier et al. · Journal of Clinical Investigation · 2018 · 382 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Protein crystallization promotes type 2 immunity and is reversible by antibody treatment

Emma K. Persson, Kenneth Verstraete, Ines Heyndrickx et al. · Science · 2019 · 304 citations · Full text

Life Sciences, Biochemistry, Immunology +10

Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritis

Ken Coppieters, Torsten Dreier, Karen Silence et al. · Arthritis & Rheumatism · 2006 · 301 citations

Medicine, Immunology, Molecular Biology +17

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

James F. Howard, Vera Bril, Ted M. Burns et al. · Neurology · 2019 · 288 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis

Klaas Vandenbroucke, Hans de Haard, Els Beirnaert et al. · Mucosal Immunology · 2009 · 284 citations · Full text

Life Sciences, Clinical Sciences, Immunology +14